{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:33:27Z","timestamp":1767598407977,"version":"3.44.0"},"reference-count":10,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,5,11]]},"abstract":"<jats:p>We present the case of 60-year-old man with type 2 diabetes who developed blistering after two sequential exposures to linagliptin. Linagliptin is one of the dipeptidyl peptidase 4 (DPP-4) inhibitors, a group of oral hypoglycaemic agents used commonly for the treatment of type 2 diabetes. On the first exposure to linagliptin, he developed blisters on the hands which resolved after stopping the drug. After repeat exposure, he developed two large blisters on the left foot, which burst giving rise to secondary infection, requiring hospital admission for treatment. We discuss the latest research linking DPP-4 inhibitors with adverse skin reactions and the effect of ulcers on the morbidity and mortality of patients with diabetes. This case report highlights skin reactions as an important, rare and lesser known side effect of DPP-4 inhibitors.<\/jats:p>","DOI":"10.1136\/bcr-2017-219998","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T03:30:22Z","timestamp":1496201422000},"page":"bcr-2017-219998","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Linagliptin-associated blistering and ulceration"],"prefix":"10.1136","volume":"2017","author":[{"given":"Cristina","family":"Psomadakis","sequence":"first","affiliation":[{"name":"Acute Medicine Department, Whittington Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naima","family":"Shahzad","sequence":"additional","affiliation":[{"name":"Diabetes & Endocrinology Department, Barnet Hospital, Herts, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Katz","sequence":"additional","affiliation":[{"name":"Diabetes & Endocrinology Department, Barnet Hospital, Herts, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,5,31]]},"reference":[{"key":"2025082803253613000_2017.may30_3.bcr-2017-219998.1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/DMSO.S4312","article-title":"Alogliptin: a new addition to the class of Gliptins","volume":"2","author":"Andukuri","year":"2009","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2025082803253613000_2017.may30_3.bcr-2017-219998.2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1468-3083.2011.04062.x","article-title":"Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin","volume":"26","author":"Skandalis","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082803253613000_2017.may30_3.bcr-2017-219998.3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jamadermatol.2013.1073","article-title":"A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors","volume":"149","author":"Aouidad","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2025082803253613000_2017.may30_3.bcr-2017-219998.4","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.188"},{"key":"2025082803253613000_2017.may30_3.bcr-2017-219998.5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamadermatol.2015.2939","article-title":"Department of Dermatology, Sacre Coeur Hospital, Beirut","volume":"152","author":"Haber","year":"2016","journal-title":"Lebanon JAMA Dermatol"},{"key":"2025082803253613000_2017.may30_3.bcr-2017-219998.6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3315\/jdcr.2014.1166","article-title":"Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature","volume":"8","author":"Attaway","year":"2014","journal-title":"J Dermatol Case Rep"},{"key":"2025082803253613000_2017.may30_3.bcr-2017-219998.7","unstructured":"UK Yellow Card Scheme [internet]. https:\/\/yellowcard.mhra.gov.uk\/ (accessed 8 Dec 2016)."},{"key":"2025082803253613000_2017.may30_3.bcr-2017-219998.8","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"2025082803253613000_2017.may30_3.bcr-2017-219998.9","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(05)67700-8","article-title":"Wound healing and its impairment in the diabetic foot","volume":"366","author":"Falanga","year":"2005","journal-title":"The Lancet"},{"key":"2025082803253613000_2017.may30_3.bcr-2017-219998.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67698-2"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-219998","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:25:44Z","timestamp":1756376744000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-219998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,31]]},"references-count":10,"alternative-id":["10.1136\/bcr-2017-219998"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-219998","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2017,5,31]]}}}